Close Menu

NEW YORK – Waters reported on Tuesday that its first quarter revenues fell 10 percent year over year, as the company saw weak sales in China due to the SARS-CoV-2 pandemic.

Waters posted revenues of $464.9 million for the quarter compared to $513.9 million in Q1 2019, below the average Wall Street estimate of $488.5 million.

Currency translation decreased sales growth by around 2 percent, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.